{"id":169792,"date":"2025-08-06T04:07:33","date_gmt":"2025-08-06T08:07:33","guid":{"rendered":"https:\/\/44.250.171.167\/?p=169792"},"modified":"2025-08-06T04:07:33","modified_gmt":"2025-08-06T08:07:33","slug":"lupin-ltd-q1-fy26-earnings-results-51-rise-in-profits","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/lupin-ltd-q1-fy26-earnings-results-51-rise-in-profits\/","title":{"rendered":"Lupin Ltd Q1 FY26 Earnings Results &#8211; 51% rise in Profits"},"content":{"rendered":"<p>Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. Presenting below are its Q1 FY26 earnings.<\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"q1-fy26-earnings-summary-aprjun-2025\" class=\"mb-2 mt-4 text-base font-[500] first:mt-0 md:text-lg dark:font-[475] [hr+&amp;]:mt-4\">Q1 FY26 Earnings Summary<\/h2>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Consolidated Revenue from Operations:<\/strong> \u20b96,268 crore, up 11.9% year-over-year (YoY) from \u20b95,514.3 crore in Q1 FY25.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>EBITDA:<\/strong>\u00a0\u20b91,806.3 crore, up 38% YoY; EBITDA margin expanded sharply to 29.3% from 23.7% YoY.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Profit Before Tax (PBT):<\/strong>\u00a0\u20b91,415.5 crore, up 42.6% YoY.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Net Profit (PAT):<\/strong> \u20b91,221 crore, up 51.4% YoY from \u20b9805.5 crore.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Gross Profit:<\/strong>\u00a0\u20b94,391.9 crore; margin at 71.3%.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>EPS:<\/strong> \u20b926.69, up \u20b951.8% on the YOY basis.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Region Performance:<\/strong><\/p>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>U.S. Revenue:<\/strong>\u00a0\u20b92,404 crore (+24.3% YoY), 39% of global sales.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>India Revenue:<\/strong>\u00a0\u20b92,089 crore (+7.8% YoY), 34% of global sales.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Other Developed Markets:<\/strong>\u00a0\u20b9775 crore (+17.4% YoY).<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Emerging Markets:<\/strong>\u00a0\u20b9652 crore (+5.2% YoY).<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>API Segment:<\/strong>\u00a0\u20b9243 crore, down 33% YoY.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Expenses:<\/strong><\/p>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Personnel Costs:<\/strong>\u00a0\u20b91,083 crore, 17.6% of sales.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Manufacturing &amp; Other Expenses:<\/strong>\u00a0\u20b91,772 crore, 28.7% of sales.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>R&amp;D Investment:<\/strong>\u00a0\u20b9484 crore, 7.9% of sales.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Operational Highlights:<\/strong>\u00a0Robust US generics and India formulations growth; highest-ever Q1 US sales; focus on cost optimization and product mix improvement.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Balance Sheet:<\/strong>\u00a0Net debt position improved to a net cash balance (-\u20b91,238.6 crore).<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<h3 id=\"key-management-commentary--strategic-highlights\" class=\"mb-2 mt-4 text-base font-[500] first:mt-0 md:text-lg dark:font-[475] [hr+&amp;]:mt-4\">Key Management Commentary &amp; Strategic Highlights<\/h3>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Managing Director Nilesh Gupta:<\/strong>\u00a0\u201cWe continue to build strong business momentum, anchored by a robust product portfolio, improved efficiencies, and effective use of assets and investments. Our sharpened focus on compliance, innovation, and technology positions us to further unlock sustainable growth.\u201d<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Growth Drivers:<\/strong>\u00a0US business momentum (new launches, strong generics pipeline, leading share in key molecules); steady Indian branded business; cost management; <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/0722fe03-4c2d-46bf-954d-977d3a04e9fa.pdf\" target=\"_blank\" rel=\"noopener\">margin expansion<\/a> from operational efficiencies.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Strategic Focus:<\/strong>\u00a0Increasing investment in R&amp;D for specialty and complex generics, further strengthening of quality\/compliance, and digitalization of operations. Management strikes an optimistic outlook on sustaining <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/0722fe03-4c2d-46bf-954d-977d3a04e9fa.pdf\" target=\"_blank\" rel=\"noopener\">double-digit growth and margin improvement<\/a> in coming quarters.<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-large wp-image-169793\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4-839x1024.png\" alt=\"Lupin Q1 FY26 Earnings Results\" width=\"640\" height=\"781\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png 1489w\" sizes=\"auto, (max-width: 640px) 100vw, 640px\" \/><\/p>\n<p>&nbsp;<\/p>\n<h2 id=\"q4-fy25-earnings-snapshot-janmar-2025\" class=\"mb-2 mt-4 text-base font-[500] first:mt-0 md:text-lg dark:font-[475] [hr+&amp;]:mt-4\">Q4 FY25 Earnings Summary<\/h2>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Revenue from Operations:<\/strong>\u00a0\u20b95,667 crore, up 14.2% YoY.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Net Profit (PAT):<\/strong>\u00a0\u20b9782 crore, up 112% YoY from \u20b9368 crore.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>EBITDA:<\/strong>\u00a0\u20b91,378 crore, margin at 24.8% (up from 21% YoY).<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Region Highlights:<\/strong>\u00a0North America revenue up 19% YoY (\u20b92,261 crore), India up 6.9% YoY (\u20b91,711 crore).<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Full Year FY25:<\/strong>\u00a0Sales \u20b922,192 crore (+12.9% YoY); PAT \u20b93,306 crore (+70.8% YoY); EBITDA \u20b95,479 crore (+39.4% YoY); margin up 469 basis points to 24.7%.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:pb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:pb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-0 py-2\"><strong>Management Commentary:<\/strong>\u00a0Q4 and FY25 marked by strong growth in both topline and profitability due to new products and improved margins through operational excellence.<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>To view the previous earnings of the company, <a href=\"https:\/\/44.250.171.167\/symbol\/lupin\/\">click here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. Presenting below are its Q1 [&hellip;]<\/p>\n","protected":false},"author":1863,"featured_media":169793,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,5747],"tags":[11776,10162],"class_list":["post-169792","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-healthcare-stocks","tag-active-pharmaceutical-ingredients","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":172213,"url":"https:\/\/alphastreet.com\/india\/lupin-q2-fy26-earnings-results\/","url_meta":{"origin":169792,"position":0},"title":"Lupin Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 7, 2025","format":false,"excerpt":"Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Lupin Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":143124,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-lupin-limited-for-q3-fy23\/","url_meta":{"origin":169792,"position":1},"title":"Earnings Summary Of Lupin Limited For Q3 FY23","author":"Hardik Bhandare","date":"March 1, 2023","format":false,"excerpt":"Lupin Limited is a pharmaceutical company headquartered in Mumbai, India. The company was founded in 1968 and has operations in over 100 countries. Lupin is primarily engaged in the development, manufacture, and marketing of generic and branded pharmaceuticals, biosimilars, and specialty pharmaceuticals. The company has a diversified portfolio of products\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":170582,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-q1-fy26-earnings-results\/","url_meta":{"origin":169792,"position":2},"title":"Alkem Laboratories Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Alkem Laboratories Ltd is a global pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b93,371 crore, up 11.18% year-on-year (YoY) from \u20b93,032 crore in Q1 FY25. Total Expenses: \u20b92,750 crore, up 8.61%\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"ALKEM Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":171315,"url":"https:\/\/alphastreet.com\/india\/emcure-q1-fy26-earnings-results-2\/","url_meta":{"origin":169792,"position":3},"title":"Emcure Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 17, 2025","format":false,"excerpt":"Company Overview: Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally, serving diverse therapeutic segments. Presenting below its Q1 FY26 Earnings Results. Financial Highlights for Q1 FY26: Revenue: \u20b92,101 crore, up 15.76% year-on-year from \u20b91,815 crore Total Expenses: \u20b91,810 crore, up 10.91% year-on-year from \u20b91,632 crore Consolidated\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"EMCURE Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170544,"url":"https:\/\/alphastreet.com\/india\/akums-q1-fy26-earnings-results\/","url_meta":{"origin":169792,"position":4},"title":"Akums Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Ltd, established in 2004, is a pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b91,024 crore, up 0.49% year-on-year (YoY) from \u20b91,019 crore in Q1 FY25.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AKUMS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170447,"url":"https:\/\/alphastreet.com\/india\/aarti-drugs-q1-fy26-earnings-results\/","url_meta":{"origin":169792,"position":5},"title":"Aarti Drugs Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 21, 2025","format":false,"excerpt":"Aarti Drugs Ltd, established in 1984 and part of the $1000 million Aarti Group of Industries, is engaged in manufacturing and selling Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals, as well as pharmaceutical formulations. Presenting below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b9591 crore,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AARTIDRUGS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=169792"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169792\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/169793"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=169792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=169792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=169792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}